TASCENSO ODT
Peakfingolimod lauryl sulfate
NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Drug data last refreshed 6h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TASCENSO ODT is an orally disintegrating tablet formulation of fingolimod lauryl sulfate, a small-molecule sphingosine-1-phosphate receptor modulator. The product was approved in December 2021 and represents a novel dosage form designed to improve patient convenience and compliance. Fingolimod is indicated for multiple sclerosis and other immune-mediated conditions, working by sequestering lymphocytes in lymph nodes to reduce central nervous system infiltration.
$0.481MPart D
Peak9.3 years to LOEPeak lifecycle stage with minimal Medicare Part D penetration suggests emerging adoption trajectory; brand team likely focused on awareness and patient access programs rather than high-volume scaling.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TASCENSO ODT offers career opportunities in commercial and medical affairs roles focused on building awareness and adoption of a differentiated dosage form in the growing MS therapeutic market. With zero competitive pressure and a 9+ year patent runway, career trajectories support stable product team growth and strategic commercial initiatives without immediate LOE pressures.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.